In particular, the kinases CDK1 and CDK2 were found to be among the top relevant kinases in a panel of T-ALL samples, and their inhibition by milciclib counteracted survival in cell lines and patient-derived xenografts of T-ALL [75], thus suggesting the targeting of these CDKs for pharmacological intervention in T-cell hematological malignancies. This evidence concerns the gene CDK2 and acute lymphoblastic leukemia.